Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies

Area of Science:

• Genetics
• Molecular Biology
• Biotechnology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by dystrophin gene mutations, leading to progressive muscle degeneration and premature death.
• Current treatments for DMD are limited and do not offer a cure, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review the latest advancements in CRISPR-based gene-editing strategies for Duchenne muscular dystrophy.
• To analyze the potential and challenges of using CRISPR/Cas technology for DMD therapeutics.

Main Methods:

• Preclinical studies utilizing CRISPR-based approaches in various models (human cells, murine, large animals).
• Analysis of gene editing efficiency, off-target effects, and immunogenicity concerns.

Main Results:

• CRISPR technology has demonstrated potential in preclinical models to restore dystrophin expression, offering hope for DMD treatment.
• Significant challenges including immunogenicity, off-target mutations, and delivery efficiency need to be addressed for clinical translation.

Conclusions:

• CRISPR gene editing holds significant promise as a potential curative therapy for Duchenne muscular dystrophy.
• Continued research and development in gene-editing technologies, delivery systems, and safety evaluations are crucial for successful clinical application.